المؤلفون: Ibrahim M; Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA., Murphree C; Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA., Patel K; Delta Pathology Group, Shreveport, Louisiana, USA., Mastrodomenico M; Delta Pathology Group, Shreveport, Louisiana, USA., Saba NS; Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA., Safah H; Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA., Schmid J; Pathology Department, Tulane University, New Orleans, Louisiana, USA., Socola F; Hematology and Bone Marrow Transplant, University of California Davis, Sacramento, California, USA.

المصدر: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2024 Sep; Vol. 7 (9), pp. e2054.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101747728 Publication Model: Print Cited Medium: Internet ISSN: 2573-8348 (Electronic) Linking ISSN: 25738348 NLM ISO Abbreviation: Cancer Rep (Hoboken) Subsets: MEDLINE

مواضيع طبية MeSH: B7-H1 Antigen*/genetics , B7-H1 Antigen*/metabolism , Janus Kinase 2*/genetics , Janus Kinase 2*/metabolism , Primary Myelofibrosis*/genetics , Primary Myelofibrosis*/metabolism , Primary Myelofibrosis*/pathology, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Mutation ; Bone Marrow/pathology ; Megakaryocytes/pathology ; Megakaryocytes/metabolism ; Aged, 80 and over ; Case-Control Studies

المؤلفون: Gupta V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Yacoub A; Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Hospital, Kansas City, KS, USA., Mesa RA; Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Harrison CN; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Vannucchi AM; Department of Experimental and Clinical Medicine, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Università di Firenze, Florence, Italy., Kiladjian JJ; Department of Hematology, Hôpital Saint-Louis, Université Paris Cité, Paris, France., Deeg HJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Fazal S; Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, USA., Foltz L; Division of Hematology, University of British Columbia, Vancouver, Canada., Mattison RJ; Department of Internal Medicine and Medical Oncology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA., Miller CB; Department of Medical Oncology, Ascension Saint Agnes Cancer Institute, Baltimore, MD, USA., Parameswaran V; Department of Hematology, Transplantation, and Oncology, Avera Cancer Institute, Sioux Falls, SD, USA., Brown P; Bristol Myers Squibb, Princeton, NJ, USA., Hernandez C; Bristol Myers Squibb, Princeton, NJ, USA., Wang J; Bristol Myers Squibb, Princeton, NJ, USA., Talpaz M; Department of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1314-1324. Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/diagnosis , Pyrazoles*/therapeutic use , Pyrazoles*/adverse effects , Pyrazoles*/administration & dosage , Pyrimidines*/therapeutic use , Pyrimidines*/adverse effects , Pyrimidines*/administration & dosage , Nitriles* , Pyrrolidines*/therapeutic use, Humans ; Male ; Female ; Aged ; Middle Aged ; Treatment Outcome ; Sulfonamides/therapeutic use ; Sulfonamides/adverse effects ; Sulfonamides/administration & dosage ; COVID-19/epidemiology ; Aged, 80 and over ; SARS-CoV-2 ; Spleen/pathology ; Spleen/drug effects ; Adult ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/administration & dosage ; Benzenesulfonamides

المؤلفون: Zhang F; Fujian Provincial Key Laboratory on Hematology, Fujian Medical Center of Hematology, Fujian Institute of Hematology, Clinical Research Center for Hematological Malignancies of Fujian Province, Fujian Medical University Union Hospital, Fuzhou, China., Wang YZ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China., Chang Y; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China., Yuan XY; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China., Shi WH; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China., Shi HX; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China., Shen JZ; Fujian Provincial Key Laboratory on Hematology, Fujian Medical Center of Hematology, Fujian Institute of Hematology, Clinical Research Center for Hematological Malignancies of Fujian Province, Fujian Medical University Union Hospital, Fuzhou, China., Liu YR; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

المصدر: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 Jul; Vol. 106 (4), pp. 272-281. Date of Electronic Publication: 2024 Apr 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 101235690 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4957 (Electronic) Linking ISSN: 15524949 NLM ISO Abbreviation: Cytometry B Clin Cytom Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/diagnosis , Primary Myelofibrosis*/pathology , Primary Myelofibrosis*/blood , Primary Myelofibrosis*/genetics , Flow Cytometry*/methods , Immunophenotyping*/methods, Humans ; Middle Aged ; Female ; Male ; Aged ; Adult ; Retrospective Studies ; Polycythemia Vera/diagnosis ; Polycythemia Vera/pathology ; Polycythemia Vera/genetics ; Polycythemia Vera/blood ; Aged, 80 and over ; Diagnosis, Differential ; Random Forest

المؤلفون: Yan J; Department of Internal Medicine, Montefiore Medical Center, Bronx, NY, USA., Hammami MB; Department of Medicine, Jacobi Medical Center, Bronx, NY, USA., Wei JX; Department of Internal Medicine, Montefiore Medical Center, Bronx, NY, USA., Shah N; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Goldfinger M; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Mantzaris I; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Kornblum N; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Gritsman K; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Sica A; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Cooper D; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Feldman E; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Konopleva M; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Pradhan K; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Thakur R; Department of Medicine, Jacobi Medical Center, Bronx, NY, USA., Vegivinti C; Department of Medicine, Jacobi Medical Center, Bronx, NY, USA., Qasim A; Department of Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE., Verma A; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA., Goel S; Department of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA. Swgoel@montefiore.org.; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, 3411 Wayne Avenue, Bronx, NY, 10467-2509, USA. Swgoel@montefiore.org.

المصدر: Annals of hematology [Ann Hematol] 2024 Sep; Vol. 103 (9), pp. 3543-3551. Date of Electronic Publication: 2024 Jul 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/epidemiology , Primary Myelofibrosis*/mortality , SEER Program*, Humans ; Male ; Female ; Aged ; Middle Aged ; Retrospective Studies ; Survival Rate ; Aged, 80 and over ; Socioeconomic Factors ; Adult ; Databases, Factual ; United States/epidemiology ; Incidence

المؤلفون: Coltoff A; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA., Kuykendall A; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1258-1269. Date of Electronic Publication: 2024 May 13.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Janus Kinase Inhibitors*/therapeutic use , Janus Kinase Inhibitors*/pharmacology , Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/metabolism , Janus Kinases*/antagonists & inhibitors , Janus Kinases*/metabolism , Signal Transduction*/drug effects, Humans ; STAT Transcription Factors/metabolism ; Molecular Targeted Therapy/methods ; Treatment Outcome ; Animals

المؤلفون: Wang Z; West China Hospital, Sichuan University, Chendu, Sichuan, China., Jin X; West China Hospital, Sichuan University, Chendu, Sichuan, China., Zeng J; West China Hospital, Sichuan University, Chendu, Sichuan, China., Xiong Z; West China Hospital, Sichuan University, Chendu, Sichuan, China., Chen X; West China Hospital, Sichuan University, Chendu, Sichuan, China. xinchuan_chen@163.com.

المصدر: Annals of hematology [Ann Hematol] 2024 Sep; Vol. 103 (9), pp. 3293-3301. Date of Electronic Publication: 2024 Mar 18.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/therapy , Primary Myelofibrosis*/drug therapy , Hematopoietic Stem Cell Transplantation* , Janus Kinase Inhibitors*/therapeutic use , Nitriles*/therapeutic use , Pyrimidines*/therapeutic use , Pyrazoles*/therapeutic use, Humans ; Allografts ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 1/antagonists & inhibitors

المؤلفون: Harrison CN; Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK. claire.harrison@gstt.nhs.uk., Vannucchi AM; University of Florence, Florence, Italy., Recher C; University Hospital Center (CHU) of Toulouse, Toulouse, France., Passamonti F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milan, Italy., Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Hernandez-Boluda JC; Hospital Clìnico de Valencia-INCLIVA, University of Medicine, Valencia, Spain., Yacoub A; University of Kansas, Kansas City, KS, USA., Sirhan S; Jewish General Hospital, McGill University, Montreal, QC, Canada., Ellis C; GSK plc, Philadelphia, PA, USA., Patel B; GSK plc, Philadelphia, PA, USA., Strouse B; GSK plc, Philadelphia, PA, USA., Platzbecker U; University Hospital Leipzig, Leipzig, Germany.

المصدر: Advances in therapy [Adv Ther] 2024 Sep; Vol. 41 (9), pp. 3722-3735. Date of Electronic Publication: 2024 Jul 11.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Comparative Study; Multicenter Study

بيانات الدورية: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE

مواضيع طبية MeSH: Pyrimidines*/therapeutic use , Nitriles*/therapeutic use , Pyrazoles*/therapeutic use , Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/complications , Anemia*/drug therapy , Anemia*/etiology , Janus Kinase Inhibitors*/therapeutic use, Humans ; Male ; Female ; Aged ; Middle Aged ; Benzamides/therapeutic use ; Janus Kinase 1/antagonists & inhibitors ; Erythrocyte Transfusion/statistics & numerical data ; Aged, 80 and over ; Treatment Outcome ; Janus Kinase 2/antagonists & inhibitors

المؤلفون: Wang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China., Fang L; State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China., Shi H; Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China., Liu Y; Department of Hematology, Yantai Yuhuangding Hospital, Yantai, China., Long C; Department of Hematology, Huizhou First People's Hospital, Huzhou, China., Guo S; Department of Hematology, People's hospital of Zhengzhou, Zhengzhou, China., Yang X; Department of Hematology, Harbin Institute of Hematology and Oncology, Harbin, China., Hu Q; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China., Liu Z; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China., Yang C; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China., Chen M; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China., Han B; Department of Hematology, Peking Union Medical College Hospital, Chinese Academe of Medical Science and Peking Union Medical College, Beijing, 100730, China. hanbing_li@sina.com.

المصدر: Annals of hematology [Ann Hematol] 2024 Sep; Vol. 103 (9), pp. 3605-3613. Date of Electronic Publication: 2024 Jun 22.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/complications , Recombinant Fusion Proteins*/therapeutic use , Recombinant Fusion Proteins*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Retrospective Studies ; China ; Anemia, Refractory/drug therapy ; Activin Receptors, Type II/therapeutic use ; Immunoglobulin Fc Fragments/therapeutic use ; Treatment Outcome ; Follow-Up Studies ; Anemia/drug therapy ; Anemia/etiology

المؤلفون: Sansone V; Department of Medical and Surgical Studies, Alma Mater Studiorum - Università di Bologna, Bologna, Italy. vito.sansone2@unibo.it.; Gastroenterology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. vito.sansone2@unibo.it., Auteri G; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Tovoli F; Department of Medical and Surgical Studies, Alma Mater Studiorum - Università di Bologna, Bologna, Italy.; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Mazzoni C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Paglia S; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Di Pietro C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Vianelli N; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Piscaglia F; Department of Medical and Surgical Studies, Alma Mater Studiorum - Università di Bologna, Bologna, Italy.; Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

المصدر: Journal of ultrasound [J Ultrasound] 2024 Sep; Vol. 27 (3), pp. 715-722. Date of Electronic Publication: 2024 Jul 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: Italy NLM ID: 101315005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-7931 (Electronic) Linking ISSN: 18767931 NLM ISO Abbreviation: J Ultrasound Subsets: MEDLINE

مواضيع طبية MeSH: Elasticity Imaging Techniques*/methods , Spleen*/diagnostic imaging , Spleen*/pathology , Primary Myelofibrosis*/diagnostic imaging , Primary Myelofibrosis*/pathology , Liver*/diagnostic imaging , Liver*/pathology , Myeloproliferative Disorders*/diagnostic imaging , Severity of Illness Index*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over

المؤلفون: Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Galli N; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Bucelli C; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy., Fidanza CA; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Bellani V; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy., Artuso S; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy., Bianchi P; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy., Consonni D; Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Passamonti F; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy. alessandra.iurlo@policlinico.mi.it.

المصدر: Annals of hematology [Ann Hematol] 2024 Aug; Vol. 103 (8), pp. 2787-2795. Date of Electronic Publication: 2024 Jun 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Nitriles*/therapeutic use , Pyrazoles*/therapeutic use , Pyrimidines*/therapeutic use , Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/blood , Primary Myelofibrosis*/mortality , Erythrocyte Indices*, Humans ; Male ; Female ; Middle Aged ; Aged ; Prognosis ; Aged, 80 and over ; Adult